Yosemite
Yosemite is a San Francisco oncology venture capital firm founded in 2023, combining venture investment with philanthropic grantmaking across cancer research, companies and therapies.
Yosemite is an oncology-focused venture capital firm founded in 2023 and based in San Francisco, California. The firm's stated objective is to make cancer nonlethal, and its approach combines conventional venture investment with philanthropic grantmaking to support research, companies and therapies across the oncology ecosystem. Support extends from early nonprofit grantees through late-stage companies.
The firm's technical focus covers oncology and immuno-oncology, cell therapy, artificial intelligence applications in cancer, and translational therapy development. Yosemite draws on a network of researchers and entrepreneurs and works through external partnerships; in March 2024 it announced a two-year competitive research award programme run with the American Cancer Society, with an initial commitment of $13.2 million. The programme is directed at high-risk, high-reward research, including transformative AI applications in cancer, immuno-oncology and cell therapy.
Yosemite operates at the intersection of biotech venture investing and nonprofit research funding, spanning the life sciences, biotechnology, healthcare and pharmaceutical sectors. The blended investment-and-grantmaking model and the early-to-late-stage span of its support distinguish its mandate within oncology venture capital.